Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,387,503 papers from all fields of science
Search
Sign In
Create Free Account
tolcapone
Known as:
Tolcapon
, Tolcapona
, Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-
Expand
A benzophenone derivative and a catechol-O-methyltransferase (COMT) inhibitor. Tolcapone selectively and reversibly inhibits COMT, an enzyme that…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Broader (4)
Antiparkinson Agents
Benzophenones
Catechol-O-methyltransferase inhibitor
Nitrophenols
Catechol O-Methyltransferase Inhibitors [MoA]
Drug Allergy
Parkinson Disease
tolcapone 100 MG Oral Tablet [Tasmar]
Narrower (1)
SOM0226
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Validation Of An In-Vitro Canine Primary Hepatocyte-Based Co-Culture System For Use In Extended DMPK/Tox Studies
E. Novik
,
F. Atienzar
,
+5 authors
M. Yarmush
2011
Corpus ID: 59406120
To reduce the use of whole animals and the costs associated with them researchers are constantly working on the development of…
Expand
2009
2009
Reconsideraciones en el tratamiento de la enfermedad de Parkinson con levodopa: evidencias farmacodinámicas
M. Zappia
,
Alessandra Nicoletti
,
D. Muñoz S.
,
John Tapia Núñez
2009
Corpus ID: 67884844
Objetivo. Realizar una revision actualizada de la bibliografia sobre el uso de levodopa en el tratamiento de la enfermedad de…
Expand
2004
2004
The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines
B. Friedgen
,
R. Wölfel
,
K. Graefe
Naunyn-Schmiedeberg's Archives of Pharmacology
2004
Corpus ID: 36695077
To study the effects of inhibition of catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) on the removal of…
Expand
2004
2004
Rapid treatment of “off” episodes
M. Stacy
,
S. Factor
Neurology
2004
Corpus ID: 71640911
During the past 7 years, five new drugs have been approved by the United States Food and Drug Administration for the treatment of…
Expand
1999
1999
Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
Movement Disorders
1999
Corpus ID: 31843322
The catechol-O-methyltransferase inhibitor tolcapone was compared with the dopamine agonist bromocriptine in an open-label…
Expand
Review
1999
Review
1999
[Recent advances in Parkinson disease].
I. Litvan
Revista de neurología (Ed. impresa)
1999
Corpus ID: 7339286
OBJECTIVE To evaluate the latest advances in the diagnosis and symptomatic pharmacological treatment of patients with Parkinson's…
Expand
1998
1998
[Tolcapon potentiates the Levodopa effect].
Der Nervenarzt
1998
Corpus ID: 5599091
Review
1996
Review
1996
Controversies in the treatment of Parkinson's disease
M. Hely
,
J. G. Morris
Current Opinion in Neurology
1996
Corpus ID: 46527589
Although theoretical reasons exist for believing that selegiline slows the progression of Parkinson's disease, this has not been…
Expand
1995
1995
Tolcapone, an inhibitor of catechol: O‐methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert
I. Khromova
,
P. Rauhala
,
N. Zolotov
,
P. Männistö
NeuroReport
1995
Corpus ID: 26492839
&NA; Repeated administration of tolcapone, an inhibitor of catechol‐O‐methyltransferase, was able to partially restore the memory…
Expand
1994
1994
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP+-lesioned mice
N. Himori
,
Koichi Mishima
Experientia
1994
Corpus ID: 12874006
Orally administered Madopar (levodopa/benserazide 4∶1) dose-dependently antagonized haloperidol-induced (1 mg/kg s.c.) catalepsy…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE